Evidence map›Paper›PMID 39251725›Full record

ArticleScientific reports2024

Serum neurofilament light chain as a sensitive biomarker for neuromonitoring during extracorporeal membrane oxygenation.

Stefanie Fischer, Lars Heubner, Stephanie May, Puya Shalchi Amirkhiz, Jens Kuhle, Pascal Benkert, Tjalf Ziemssen, Peter Spieth, Katja Akgün

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Stefanie FischerCenter of Clinical Neuroscience, Department of Neurology, University Hospital Carl Gustav Carus, Technical University of Dresden, Fetscherstr. 74, 01307, Dresden, Germany. Stefanie.Fischer@ukdd.de.
Lars HeubnerDepartment of Anesthesiology, University Hospital and Faculty of Medicine Carl Gustav Carus of TU Dresden, Dresden, Germany.
Stephanie MayDepartment of Anesthesiology, University Hospital and Faculty of Medicine Carl Gustav Carus of TU Dresden, Dresden, Germany.
Puya Shalchi AmirkhizCenter of Clinical Neuroscience, Department of Neurology, University Hospital Carl Gustav Carus, Technical University of Dresden, Fetscherstr. 74, 01307, Dresden, Germany.
Jens KuhleMultiple Sclerosis Centre and Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB), Departments of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland.
Pascal BenkertDepartment of Clinical Research, Clinical Trial Unit, University Hospital Basel, University of Basel, Basel, Switzerland.
Tjalf ZiemssenCenter of Clinical Neuroscience, Department of Neurology, University Hospital Carl Gustav Carus, Technical University of Dresden, Fetscherstr. 74, 01307, Dresden, Germany.
Peter Spieth *Department of Anesthesiology, University Hospital and Faculty of Medicine Carl Gustav Carus of TU Dresden, Dresden, Germany.
Katja Akgün *Center of Clinical Neuroscience, Department of Neurology, University Hospital Carl Gustav Carus, Technical University of Dresden, Fetscherstr. 74, 01307, Dresden, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The use of extracorporeal membrane oxygenation (ECMO) has grown rapidly, driven by the COVID-19 pandemic. Despite its widespread adoption, neurological complications pose a significant risk, impacting both mortality and survivors' quality of life. Detecting these complications is challenging due to sedation and the heterogeneous nature of ECMO-associated neurological injury. Still, consensus of neurologic monitoring during ECMO is lacking since utilization and effectiveness of current neuromonitoring methods are limited. Especially in view of the heterogeneous nature of neurological injury during ECMO support an easily acquirable biomarker tracing neuronal damage independently from the underlying pathomechanism would be favorable. In a single-center prospective study on 34 severe acute respiratory distress syndrome (ARDS) patients undergoing ECMO, we explored the potential of serum neurofilament light chain levels (NfL) as a biomarker for neurological complications and its predictive power towards the overall outcome of ECMO patients. Individuals experiencing neurological complications (41%) demonstrated a notable rise in NfL levels (T

Indexed as

BiomarkersCOVID-19Extracorporeal Membrane OxygenationNeurofilament ProteinsAdultAgedFemaleHumansMaleMiddle AgedProspective StudiesRespiratory Distress SyndromeSARS-CoV-2Biomarkersneurofilament protein LNeurofilament ProteinsBiomarkers [D23.101]Diagnostic techniquesExtracorporeal membrane oxygenation [E04.292.451; E02.880.301]Neurological [E01.370.376]

Identifiers

PMID39251725
PMCPMC11384786

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.